[Therapeutic management of malignant paragangliomas: an illustrative case and literature review].
Prise en charge thérapeutique des paragangliomes malins: revue de littérature à travers un cas illustratif.
Adult
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Combined Modality Therapy
Cytoreduction Surgical Procedures
/ methods
Dacarbazine
/ administration & dosage
Female
Humans
Neoplasm Recurrence, Local
Paraganglioma
/ diagnostic imaging
Peptides, Cyclic
/ administration & dosage
Positron Emission Tomography Computed Tomography
/ methods
Somatostatin
/ administration & dosage
Treatment Outcome
Malignant paraganglioma
internal radiotherapy chemotherapy
surgery
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
01
2016
accepted:
31
05
2016
entrez:
22
6
2019
pubmed:
22
6
2019
medline:
4
7
2019
Statut:
epublish
Résumé
Malignant paragangliomas pose a real challenge for the practitioners. They are rare complex tumors, very heterogeneous in their evolution and prognosis. Given the rarity of this tumor group, there is no consensus on therapeutic management. Through this illustrative case study, we report the case of a 29 year old female patient followed for malignant paraganglioma due to which she initially had surgery. After a six month interval, multifocal recurrence was detected on Octreoscan PET-CT (Positron Emission Tomography- Computer Tomography). The patient underwent monthly injection of Somatuline for one year and then discontinued therapy due to disease progression. Cytoreduction was then performed followed by radiotherapy. After a year, the patient had massive disease progression. Dacarbazine-based chemotherapy was initiated. The patient had an almost complete metabolic response after eight cycles. This study aims to highlight the different therapeutic options in the management of malignant paragangliomas.
Identifiants
pubmed: 31223354
doi: 10.11604/pamj.2019.32.62.8812
pii: PAMJ-32-62
pmc: PMC6560965
doi:
Substances chimiques
Peptides, Cyclic
0
lanreotide
0G3DE8943Y
Somatostatin
51110-01-1
Dacarbazine
7GR28W0FJI
Types de publication
Case Reports
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
62Déclaration de conflit d'intérêts
Les auteurs ne déclarent aucun conflit d'intérêts.
Références
Med Pediatr Oncol. 2002 Aug;39(2):120-4
pubmed: 12116060
Endocr Relat Cancer. 2006 Jun;13(2):535-40
pubmed: 16728580
Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):155-9
pubmed: 17427102
Q J Nucl Med Mol Imaging. 2008 Dec;52(4):334-40
pubmed: 18480742
J Clin Endocrinol Metab. 2009 May;94(5):1701-5
pubmed: 19258401
Horm Metab Res. 2012 May;44(5):405-10
pubmed: 22566196
Cancer. 2012 Dec 15;118(24):6162-70
pubmed: 22736481
J Oncol. 2012;2012:872713
pubmed: 22851969
J Clin Endocrinol Metab. 2012 Nov;97(11):4040-50
pubmed: 22965939
Clin Endocrinol (Oxf). 2014 Apr;80(4):487-501
pubmed: 24118038
Int J Cancer. 2014 Dec 1;135(11):2711-20
pubmed: 24752622
Eur J Endocrinol. 2014 Sep;171(3):R111-22
pubmed: 24891137
J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42
pubmed: 24893135
Clin Endocrinol (Oxf). 2014 Nov;81(5):642-51
pubmed: 25041164
Eur J Endocrinol. 2014 Dec;171(6):R231-43
pubmed: 25063320
Nat Rev Endocrinol. 2015 Feb;11(2):101-11
pubmed: 25385035